Mr. Peter Rubinstein
Mr Rubinstein was appointed to the Board on 31 January 2018 and appointed as Chairman in April 2020. He has over 20 years’ experience in early stage technology commercialisation through to public listings on the ASX. He is a lawyer, having worked at a large national firm prior to moving in-house at Montech, the commercial arm of Monash University.
Mr Rubinstein has had significant exposure to the creation, launch and management of a diverse range of technology companies in biotech, digital payments and renewable energy. Mr Rubinstein is also a Non-Executive Director of DigitalX Limited (ASX: DCC).
Dr Muchnicki was appointed to the Board on 31 January 2018 and acted as Interim Chief Executive Officer from September 2019 till the appointment of Mr Simon Morriss to the role. George graduated from Monash University and has held positions in private practice for over 25 years and was Head of Student Health at The University of Melbourne. For the past 14 years he has been involved in commercialisation and funding R&D in the biotechnology sector from gene silencing to regenerative medicine.
Dr Muchnicki brings with him strong commercial and medical skills, including broad interests in software development, blockchain and sustainable building materials. He is a co-founder and Non-Executive Director of Speed Panel Holdings a world leader in fire rated and acoustic wall solutions. He is also the co-founder of Candlebets, a software development company that is creating blockchain enabled platforms for the gaming industry.
Dr. Jerzy “George” Muchnicki
Executive Director & Chief Medical Officer
Dr. Lindsay Wakefield
Non – Executive Director
Dr Wakefield was appointed to the Board on 24 September 2014. He started Safetech in 1985 and over the next 25 years Safetech became a force in the Australian material handling and lifting equipment market, designing and manufacturing a wide range of industrial products. In 1993, he left medicine to become the full time CEO of Safetech. In 2006 Safetech was awarded the Telstra Australian National Business of the Year. In 2013 Safetech merged and ultimately acquired Tieman Materials Handling.
Dr Wakefield continues as the CEO of Safetech. It is Australia’s largest manufacturer and supplier of dock equipment, freight hoists and custom lifting solutions. Safetech employs approximately 100 people. Dr Wakefield has been a biotech investor for more than 20 years.
Mr Nick Burrows
B.Com, FAICD, FCA, FGIA, FTIA, F Fin
Non – Executive Director
Mr Burrows has over 30 years' commercial experience and was appointed to the Board on 1st September 2019. He is a contemporary independent Non-Executive Director across the Listed, Government and Private sectors with significant expertise in corporate governance, and strategic, commercial, financial and risk management oversight, underpinned by his background as a chartered accountant and registered company auditor.
Mr Burrows was Chief Financial Officer and Company Secretary of Tassal Group Limited for 21 years from 1988 to 2009. Mr Burrows current and past Board and advisory portfolio spans listed entities, regulated entities, GBE’s, State-owned and local Government entities and authorities, large private / family companies, community organisations, membership-based bodies and Not-for-Profits.
Mr Simon Morriss
Chief Executive Officer
Mr Morriss was appointed as Chief Executive Officer on 1 February 2021 and brings over 20 years’ experience within the Pharmaceutical, Healthcare and FMCG industries having held senior executive positions at Sanofi and Blackmores. He brings a wealth of experience in managing teams and successfully executing across sales, marketing and brand building.
Additionally, Mr Morriss has been critical in leading commercialisation across these industries and understands the unique pressures and opportunities. He has led companies through strategic adaptation to execution and will be driving Genetic Technologies commercialisation strategy and continue to drive innovation across the business.
Mr Mike Tonroe
Chief Financial Officer
Mr Tonroe joined the company in June 2021, he has over 25 years’ experience in overseeing the finance function at both management and board-level positions for private and listed companies in Australia, UK, US and Canada.
Prior to his most recent role as Chief Financial Officer and Company Secretary at dual-listed Opthea Mr Tonroe was Chief Financial Officer and Company Secretary at the Australian Synchrotron in Melbourne and also has extensive accounting expertise having worked for both Deloitte and KPMG in the UK and Hong Kong.
Mr Tonroe is a fellow of the Institute of Chartered Accountants in England and Wales, a member of the Australian Institute of Company Directors and holds a graduate degree in Business Studies from Buckingham University, UK.
Mr Stanley Sack
Chief Operating Officer
Mr Stanley Sack joined the Company in March 2020 as COO. Mr Sack has worked for large private and listed companies in Executive positions including Visy Plastics, Nylex and The Laminex Group and has also managed the operations for one of Australia’s largest Family Private Equity groups.
Mr Sack's last role was within his own business as Chief Executive Officer, where he built Australia's largest national mobile health business in the aged and community care area. The business was recently sold to one of the largest health insurers in Australia.
Mr Sack has extensive experience in rebranding and refocusing businesses and developing their growth strategy. Mr Sack’s focus at GTG will be to develop key strategic business priorities and the growth and sales of our products.
Mr Justyn Stedwell
Mr Stedwell was appointed to the role of Company Secretary on July 15, 2019. Justyn is a professional Company Secretary consultant with over 10 years experience acting as a Company Secretary of ASX listed companies across a wide range of industries.He is currently the Company Secretary of several ASX listed companies.
Dr Richard Allman
Chief Scientific Officer
Dr Allman joined the Company in 2004 and was appointed Scientific Director in December 2012. He has over 20 years of scientific and research experience in both the academic arena in the UK and the commercial sector in Australia. He has wide experience in research leadership, innovation management, and intellectual property strategy, covering oncology, diagnostics, and product development. Prior to entering the biotech sector, Dr Allman’s academic career encompassed oncology research, drug development, and assay design.